---
title: "Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292316425.md"
description: "Cantor Fitzgerald analyst Steven Seedhouse reaffirmed a Buy rating on Opus Genetics (IRD) with a $15.00 price target, despite shares closing at $4.02. This aligns with a broader Strong Buy consensus among analysts, who average an $11.14 target implying significant upside. Wedbush also maintained a Buy rating with a $10.00 target."
datetime: "2026-07-10T11:36:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292316425.md)
  - [en](https://longbridge.com/en/news/292316425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292316425.md)
generator: "portal-rs"
---

# Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)

In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Opus Genetics, with a price target of $15.00. The company’s shares closed yesterday at $4.02.

### 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Seedhouse covers the Healthcare sector, focusing on stocks such as Pharvaris, Aligos Therapeutics, and Opus Genetics. According to TipRanks, Seedhouse has an average return of 12.0% and a 46.02% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Opus Genetics with a $11.14 average price target, representing a 177.11% upside. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $10.00 price target.

### Related Stocks

- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)
- [PHVS.US](https://longbridge.com/en/quote/PHVS.US.md)
- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)

## Related News & Research

- [Brokers Set Expectations for Opus Genetics FY2030 Earnings](https://longbridge.com/en/news/295653446.md)
- [Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target](https://longbridge.com/en/news/291831058.md)
- [Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19](https://longbridge.com/en/news/296655292.md)
- [KBW Reaffirms Their Buy Rating on Kayne Anderson BDC, Inc. (KBDC)](https://longbridge.com/en/news/296081216.md)
- [NYSE:MMA - MMA.INC Completes US$4.0 Million Private Placement at US$1.00 Per Share | MMA Stock News](https://longbridge.com/en/news/296495505.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**